Updated on 24 August 2014
With increased life expectancy, an ageing society, and evolving infections, there is a growing demand for novel treatments to cure diseases. The researchers' perspective towards curing and preventing ailments is fast changing as microbes develop drug resistance. A group of four young graduates from Japan have set out to resolve these challenges through their innovative start-up, Molcure, takes pride in designing antibodies for varied diseases.
Newer technologies like genetic engineering and genome sequencing aim to develop drugs with increased precision and accuracy. With many challenges and newer diseases there is more scope for innovation and research, many startups are venturing into unique specialized areas of drug development to cater to the unmet medical needs of the society.
When Molcure began its journey in engineering antibodies, little did it know that the market would favor them in the long run. The market for antibody drugs in Japan is expected to almost double by 2020.
Molcure aims to excel in this market with their key software technology called "Abtracer". This tool identifies antibodies from vast gene pool libraries, which can then be designed into antibody-drugs using biotechnology, IT, and robotics. The Abtracer technology has already attracted eyeballs, winning the University Venture Grand Prix (UVGP) Entrepreneurship award, organized by the Ministry of Economy, Trade and Industry, Japan.